NCT03071406 2026-03-11
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
Clinical Trials
13 trialsNCT04326257 2026-01-08
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
University of Pittsburgh
Phase 2 Completed
NCT02374242 2025-12-10
ABC
Melanoma Institute Australia
Phase 2 Active not recruiting
NCT03693014 2025-10-06
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05219435 2025-09-24
VEXILLUM
Spanish Oncology Genito-Urinary Group
Phase 2 Active not recruiting
NCT03570619 2025-05-08
IMPACT
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT04739618 2024-07-23
Metastatic Solid Cancer Clinical Trial
ImmunSYS, LLC
Phase 2 Active not recruiting
NCT04713371 2024-05-09
A Phase 2 Trial for Patients With Metastatic Solid Cancer
Rampart Health, L.L.C.
Phase 2 Active not recruiting
NCT03126331 2024-03-18
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02115139 2022-11-08
GRAY-B
Grupo Español Multidisciplinar de Melanoma
Phase 2 Completed
NCT03219775 2021-11-03
TITAN-TCC
AIO-Studien-gGmbH
Phase 2 Unknown
NCT01363206 2020-03-19
GIPI
Northern California Melanoma Center
Phase 2 Completed
NCT01565837 2016-02-01
SART
Comprehensive Cancer Centers of Nevada
Phase 2 Unknown